Former Abbott and J&J Executive Appointed Chief of ZEISS Vision Care US

ZEISS Vision Care has named Gary Rosenblum as president and CEO of ZEISS Vision Care U.S., succeeding Jens Roy, who spent more than a decade driving the ZEISS Vision Care business in North America, and left the company in pursuit of new opportunities.

Rosenblum brings to his leadership role relevant senior leadership experience at Demant, Johnson & Johnson, Abbott, and Pfizer to his new role. He joins ZEISS following more than eight years at Oticon, a division of Demant, where he served as president for U.S. hearing aids and led efforts to bring the company’s hearing solutions to Americans with mild-to-severe hearing loss. Under his leadership, Oticon grew market share and increased revenue, driven by new approaches in sales, talent development, and transformation. Before that, Rosenblum led the Enterprise Customer Team at Johnson & Johnson, working with the largest hospital systems on the West Coast. He’s also served as director, Global Strategic Marketing at Abbott, leading the charge in the worldwide commercialization of the company’s Diabetes Care portfolio.

“Gary’s hands-on experience in highly relevant healthcare roles and his proven track record of success make him an excellent fit to join the ZEISS Vision Care team,” ZEISS Consumer Markets CEO Sven Hermann stated. “With Gary at the helm, I am confident we will continue our positive momentum and maintain ZEISS’ leadership in the U.S. market. I am grateful for the role Jens played in transforming ZEISS Vision Care in North America over the past 10 years and wish him the best in his future endeavors.”

In his role as president and CEO, Rosenblum will focus on growing ZEISS Vision Care U.S., both in terms of the core business and future opportunities. Driven by a commitment to protect and improve eye health, he is passionate about continuing the legacy of innovation that has guided ZEISS for more than 179 years.

“I am thrilled to join ZEISS Vision Care and continue to build on the company’s mission of delivering industry-leading optical innovations to eyecare professionals and millions of Americans,” Rosenblum said. “I am impressed with our team in the U.S. and their commitment to excellence. I’d like to thank Jens for his support with this transition and look forward to continuing his record of success for the company.”

ZEISS is an international technology enterprise operating in optics and optoelectronics. In the previous fiscal year (ended Sept. 30, 2023), the ZEISS Group generated €10 billion euros in annual revenue within its four segments: Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets.

ZEISS develops, produces, and distributes solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and smart production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company’s sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS’ technology and market leadership. ZEISS invests 15% of its revenue in research and development.

With more than 43,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies, and 27 research and development facilities. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation is the sole owner of the holding company, Carl Zeiss AG.

ZEISS Vision Care manufactures eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.